Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi M E, Janzer R C, Merlo A, Van Meir E G
Department of Neurosurgery, University Hospital (CHUV), Lausanne, Switzerland.
Oncogene. 2000 Aug 3;19(33):3816-22. doi: 10.1038/sj.onc.1203700.
P16 and P14ARF are two tumor suppressors encoded by the locus ink4a-arf which is frequently deleted in human tumors. Recent experiments performed with mouse embryonic fibroblasts have shown that P14ARF is an upstream regulator of the P53 pathway. This raises the question as to whether in human tumors the loss of p14arf and mutation of p53 are mutually exclusive events which segregate with genetic alterations at other loci. To examine this question we performed a multigenic analysis on 29 gliomas. We analysed p53 and p14arf in relation with five other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26. Our study shows for the first time that p53 mutations and p14arf deletions appear mutually exclusive in human glioblastoma, suggesting that they may be functionally redundant in glioma tumorigenesis. The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV), either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%). These tumors further showed MDM2 overexpression (9.1%), egfr oncogene amplification/egfr overexpression (50%), pten mutations (27.3%) and loss of heterozygosity (LOH) at the chromosomal regions 10q23.3 (86.4%) and 10q25-26 (100%). These alterations did not segregate with p53 mutations or p14arf deletions, while p14arf and cdkn2a were always deleted.
P16和P14ARF是由ink4a-arf位点编码的两种肿瘤抑制因子,该位点在人类肿瘤中经常缺失。最近用小鼠胚胎成纤维细胞进行的实验表明,P14ARF是P53通路的上游调节因子。这就提出了一个问题,即在人类肿瘤中,p14arf的缺失和p53的突变是否是相互排斥的事件,它们是否与其他位点的基因改变相关。为了研究这个问题,我们对29例神经胶质瘤进行了多基因分析。我们分析了p53和p14arf,并将其与其他五个编码人类神经胶质瘤中最常突变基因的基因位点相关联:cdkn2a、mdm2、egfr、pten以及染色体区域10q23.3和10q25 - 26。我们的研究首次表明,p53突变和p14arf缺失在人类胶质母细胞瘤中似乎是相互排斥的,这表明它们在神经胶质瘤的肿瘤发生过程中可能具有功能冗余性。因此,在81.8%的恶性神经胶质瘤(世界卫生组织III级和IV级)中,P53通路被破坏,要么是通过p53基因的突变(31.8%),要么是通过p14arf的缺失(54.5%)。这些肿瘤还进一步表现出MDM2的过表达(9.1%)、egfr癌基因扩增/egfr过表达(50%)、pten突变(27.3%)以及染色体区域10q23.3(86.4%)和10q25 - 26(100%)的杂合性缺失(LOH)。这些改变与p53突变或p14arf缺失不相关,而p14arf和cdkn2a总是缺失。